. 2022 Jan 20;11(3):527. doi: 10.3390/jcm11030527

Table 5.

Meibomian gland atrophy in different groups of subjects.

	Percent Dropout
	Upper Lids	Lower Lids
Symptomatic	24.6% (17.8%, 38.0%)	39.9% (35.9%, 43.8%)
Asymptomatic	26.2% (21.7%, 32.9%)	40.7% (36.1%, 47.8%)
p-value ¹	0.823	0.628
MGD	26.3% (22.7%, 33.1%)	40.7% (34.9%, 47.8%)
Non-MGD	25.3% (19.0%, 35.3%)	40.1% (37.0%, 44.0%)
p-value ¹	0.693	0.965

Data are presented as median (Q1, Q3). MGD = meibomian gland dysfunction. Symptomatic group included subjects with OSDI score ≥ 13, while asymptomatic group included subjects with OSDI score < 13. ^1. Differences between males and females evaluated with Student’s t-test with normally distributed data and with Mann–Whitney test with non-normally distributed data.